コレシストキニンを不活性化するセリンペプチダースの特徴と抑制
C Rose1, F Vargas, P Facchinetti
1Unité de Neurobiologie et Pharmacologie de l'INSERM, Centre Paul Broca, Paris, France.
Nature
|April 4, 1996
まとめ
研究者らは,コレシストキニン (CCK) を不活性化する新しいペプチダースを特定した. この酵素であるトリペプチジルペプチダゼIIは,CCKの調節と飽和に役割を果たし,その抑制は飽和作用を示しています.
科学分野:
- バイオケミストリー バイオケミストリー
- 神経科学は神経科学である.
- 酵素学 酵素学とは
背景:
- コレチストキニン (CCK) は,飽和感と消化に関与する重要な腸-脳ペプチドホルモンです.
- CCKの無活性化を調節するメカニズムとその正確な生理学的役割は,まだ完全に理解されていません.
- トリペプチジルペプチダゼII (TPP-II) は,機能がほとんど不明の細胞分裂酵素である.
研究 の 目的:
- コレチストキニン (CCK) の不活性化に起因するペプチダースを特定する.
- このCCK不活性化酵素の性質と細胞の局所を特徴づけるために.
- このペプチダースを抑制してCCKの活性と飽和感を調節する可能性を調査する.
主な方法:
- 細胞源からCCK不活性化ペプチダースの浄化と識別.
- トリペプチジルペプチダゼII (TPP-II) の膜結合イソフォームとしての酵素の特徴.
- ペプチダースの特定の阻害体であるブタビンジドの設計と適用.
主要な成果:
- CCK不活性化ペプチダゼは,トリペプチジルペプチダゼII (TPP-II) の膜に結合した同型として特定されました.
- このペプチダゼは,CCK反応性ニューロンと非ニューロン細胞の両方で検出されました.
- 特定の阻害剤であるブタビンジドは,内生性CCKを不活性化から保護することに成功した.
- ブタビンジドの投与は,CCKA受容体を通して媒介された満足感をもたらす効果を示した.
結論:
- トリペプチジルペプチダゼII (TPP-II) は,コレシストキニン (CCK) の不活性化における重要な酵素である.
- 膜に結合したTPP-IIイソフォームは,神経組織と非神経組織の両方でCCK信号伝達を調節するために戦略的に局所されています.
- TPP-IIの抑制は,CCK媒介の飽和感を高めるための有効な治療戦略です.
関連する概念動画
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:29Intestinal Phase of Digestion
The intestinal phase of digestion is the third and final stage of the digestive process, occurring after the cephalic and gastric phases. It begins when chyme, a partially digested mixture of food and digestive enzymes, enters the small intestine from the stomach. This phase is crucial for nutrient absorption and involves complex hormonal and enzymatic interactions.
The arrival of the chyme in the small intestine distends the duodenum, which triggers the enterogastric reflex. This distension...
The arrival of the chyme in the small intestine distends the duodenum, which triggers the enterogastric reflex. This distension...